NatureWise Biotech & Medicals Inkomsten in het verleden
Verleden criteriumcontroles 2/6
NatureWise Biotech & Medicals's earnings have been declining at an average annual rate of -15.3%, while the Personal Products industry saw earnings growing at 11.2% annually. Revenues have been declining at an average rate of 9% per year. NatureWise Biotech & Medicals's return on equity is 2.2%, and it has net margins of 7%.
Belangrijke informatie
-15.3%
Groei van de winst
-18.8%
Groei van de winst per aandeel
Personal Products Groei van de industrie | 13.9% |
Inkomstengroei | -9.0% |
Rendement op eigen vermogen | 2.2% |
Nettomarge | 7.0% |
Laatste winstupdate | 30 Jun 2024 |
Recente prestatie-updates uit het verleden
Recent updates
Lacklustre Performance Is Driving NatureWise Biotech & Medicals Corporation's (GTSM:4732) Low P/E
Apr 29A Look At The Intrinsic Value Of NatureWise Biotech & Medicals Corporation (GTSM:4732)
Mar 25Here's Why We Don't Think NatureWise Biotech & Medicals's (GTSM:4732) Statutory Earnings Reflect Its Underlying Earnings Potential
Dec 20Opbrengsten en kosten
Hoe NatureWise Biotech & Medicals geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.
Inkomsten en omzetgeschiedenis
Datum | Inkomsten | Inkomsten | G+A Uitgaven | R&D-uitgaven |
---|---|---|---|---|
30 Jun 24 | 225 | 16 | 59 | 57 |
31 Mar 24 | 192 | 13 | 56 | 43 |
31 Dec 23 | 160 | 10 | 54 | 30 |
30 Sep 23 | 170 | 13 | 54 | 32 |
30 Jun 23 | 180 | 16 | 53 | 34 |
31 Mar 23 | 205 | 23 | 54 | 42 |
31 Dec 22 | 229 | 30 | 54 | 49 |
30 Sep 22 | 261 | 46 | 53 | 55 |
30 Jun 22 | 293 | 63 | 52 | 61 |
31 Mar 22 | 271 | 47 | 51 | 65 |
31 Dec 21 | 250 | 31 | 50 | 69 |
30 Sep 21 | 223 | 15 | 49 | 73 |
30 Jun 21 | 197 | 0 | 48 | 76 |
31 Mar 21 | 252 | 33 | 53 | 72 |
31 Dec 20 | 307 | 65 | 57 | 68 |
30 Sep 20 | 330 | 70 | 61 | 69 |
30 Jun 20 | 354 | 76 | 64 | 69 |
31 Mar 20 | 331 | 58 | 60 | 76 |
31 Dec 19 | 307 | 40 | 56 | 84 |
30 Sep 19 | 251 | 19 | 52 | 77 |
30 Jun 19 | 195 | -2 | 49 | 70 |
31 Mar 19 | 152 | -9 | 46 | 54 |
31 Dec 18 | 108 | -15 | 43 | 37 |
30 Sep 18 | 99 | -19 | 41 | 37 |
30 Jun 18 | 90 | -23 | 39 | 36 |
31 Mar 18 | 79 | -42 | 39 | 45 |
31 Dec 17 | 69 | -60 | 39 | 55 |
30 Sep 17 | 65 | -67 | 38 | 58 |
30 Jun 17 | 61 | -74 | 37 | 61 |
31 Mar 17 | 59 | -67 | 37 | 59 |
31 Dec 16 | 58 | -60 | 36 | 56 |
30 Sep 16 | 54 | -46 | 35 | 50 |
30 Jun 16 | 51 | -32 | 35 | 44 |
31 Mar 16 | 51 | -30 | 34 | 40 |
31 Dec 15 | 50 | -29 | 32 | 35 |
30 Sep 15 | 48 | -30 | 33 | 29 |
30 Jun 15 | 45 | -31 | 33 | 22 |
31 Mar 15 | 46 | -29 | 35 | 17 |
31 Dec 14 | 48 | -26 | 36 | 12 |
30 Sep 14 | 52 | -23 | 36 | 10 |
30 Jun 14 | 57 | -20 | 36 | 8 |
31 Mar 14 | 61 | -16 | 40 | 9 |
31 Dec 13 | 65 | -12 | 43 | 10 |
Kwaliteitswinsten: 4732 has high quality earnings.
Groeiende winstmarge: 4732's current net profit margins (7%) are lower than last year (8.8%).
Analyse vrije kasstroom versus winst
Analyse van de winstgroei in het verleden
Winsttrend: 4732 has become profitable over the past 5 years, growing earnings by -15.3% per year.
Versnelling van de groei: 4732's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Winst versus industrie: 4732 had negative earnings growth (-1%) over the past year, making it difficult to compare to the Personal Products industry average (-1%).
Rendement op eigen vermogen
Hoge ROE: 4732's Return on Equity (2.2%) is considered low.